| PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness J Shen, W Zhao, Z Ju, L Wang, Y Peng, M Labrie, TA Yap, GB Mills, ... Cancer research 79 (2), 311-319, 2019 | 468 | 2019 |
| Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy Y Fang, DJ McGrail, C Sun, M Labrie, X Chen, D Zhang, Z Ju, CP Vellano, ... Cancer cell 35 (6), 851-867. e7, 2019 | 180 | 2019 |
| A-to-I RNA editing contributes to proteomic diversity in cancer X Peng, X Xu, Y Wang, DH Hawke, S Yu, L Han, Z Zhou, K Mojumdar, ... Cancer cell 33 (5), 817-828. e7, 2018 | 180 | 2018 |
| Intracellular galectins in cancer cells: potential new targets for therapy MC Vladoiu, M Labrie, Y St-Pierre International journal of oncology 44 (4), 1001-1014, 2014 | 112 | 2014 |
| Epigenetic regulation of mmp-9 gene expression M Labrie, Y St-Pierre Cellular and molecular life sciences 70 (17), 3109-3124, 2013 | 74 | 2013 |
| Expression and functions of galectin-7 in ovarian cancer M Labrie, MC Vladoiu, AA Grosset, L Gaboury, Y St-Pierre Oncotarget 5 (17), 7705, 2014 | 63 | 2014 |
| Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells AA Grosset, M Labrie, D Gagné, MC Vladoiu, L Gaboury, N Doucet, ... BMC cancer 14 (1), 1-10, 2014 | 59 | 2014 |
| Galectin signatuares contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets AA Grosset, M Labrie, MC Vladoiu, EM Yousef, L Gaboury, Y St-Pierre Oncotarget 7 (14), 18183, 2016 | 56 | 2016 |
| Expression of galectin-7 is induced in breast cancer cells by mutant p53 CG Campion, M Labrie, G Lavoie, Y St-Pierre PloS one 8 (8), e72468, 2013 | 54 | 2013 |
| A mutation in the carbohydrate recognition domain drives a phenotypic switch in the role of galectin-7 in prostate cancer M Labrie, M Vladoiu, BG Leclerc, AA Grosset, L Gaboury, J Stagg, ... PloS one 10 (7), e0131307, 2015 | 43 | 2015 |
| Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma B Wang, W Zhang, G Zhang, L Kwong, H Lu, J Tan, N Sadek, M Xiao, ... Oncogene, 1-10, 2021 | 38 | 2021 |
| Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers M Labrie, LOF De Araujo, L Communal, AM Mes-Masson, Y St-Pierre Scientific reports 7 (1), 1-13, 2017 | 36 | 2017 |
| An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer BE Johnson, AL Creason, JM Stommel, JM Keck, S Parmar, CB Betts, ... bioRxiv, 2020.12. 03.408500, 2021 | 27 | 2021 |
| Systems approach to rational combination therapy: PARP inhibitors C Sun, Y Fang, M Labrie, X Li, GB Mills Biochemical Society transactions 48 (3), 1101-1108, 2020 | 26 | 2020 |
| FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer H Lai, X Zhao, Y Qin, Y Ding, R Chen, G Li, M Labrie, Z Ding, J Zhou, J Hu, ... Journal of Experimental & Clinical Cancer Research 37 (1), 1-12, 2018 | 26 | 2018 |
| Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin MC Vladoiu, M Labrie, M Létourneau, P Egesborg, D Gagné, É Billard, ... Oncotarget 6 (38), 40970, 2015 | 25 | 2015 |
| Apolipoprotein D transgenic mice develop hepatic steatosis through activation of PPARγ and fatty acid uptake M Labrie, S Lalonde, O Najyb, M Thiery, C Daneault, C Des Rosiers, ... PloS one 10 (6), e0130230, 2015 | 24 | 2015 |
| Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics A Li, JM Keck, S Parmar, J Patterson, M Labrie, AL Creason, BE Johnson, ... NPJ precision oncology 5 (1), 1-12, 2021 | 23 | 2021 |
| The CCAAT/enhancer-binding protein beta-2 isoform (CEBPβ-2) upregulates galectin-7 expression in human breast cancer cells CG Campion, M Labrie, AA Grosset, Y St-Pierre PloS one 9 (5), e95087, 2014 | 23 | 2014 |
| Binding and repressive activities of apolipoprotein E3 and E4 isoforms on the human ApoD promoter LC Levros, M Labrie, C Charfi, E Rassart Molecular neurobiology 48 (3), 669-680, 2013 | 23 | 2013 |
